<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03259568</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00082433</org_study_id>
    <nct_id>NCT03259568</nct_id>
  </id_info>
  <brief_title>Effects of rTMS on Human Brain Activity Measured With EEG and fMRI</brief_title>
  <official_title>Effects of rTMS on Human Brain Activity Measured With EEG and fMRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project investigates the effects of repetitive transcranial magnetic stimulation (rTMS)&#xD;
      on neural circuits as a function of spatiotemporal parameters and brain state in order to&#xD;
      better understand why the method works and how to improve its efficacy. Leveraging our&#xD;
      expertise in application of TMS methodology during concurrent single neuron recording&#xD;
      techniques in non-human primates and imaging and scalp potential techniques in humans (fMRI&#xD;
      and EEG), the investigators aim to resolve three interlocking problems in the design and&#xD;
      application of rTMS: stimulation frequency, spatial targeting, and interactions with brain&#xD;
      state.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Covid-19&#xD;
  </why_stopped>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute effect of a rTMS session on the performance for a motion task, as measured by accuracy (in percentage of correct responses)</measure>
    <time_frame>up to 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute effect of a rTMS session on the performance for a motion task, as measured by reaction time (in ms)</measure>
    <time_frame>up to 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute effect of a rTMS session on fMRI activation during a motion task, as measured by the change in BOLD signal</measure>
    <time_frame>up to 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute effect of a rTMS session on EEG recordings during a motion task, as measured by the change in neural oscillations</measure>
    <time_frame>up to 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Dose-response Study With rTMS</condition>
  <arm_group>
    <arm_group_label>Active rTMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Repetitive TMS</intervention_name>
    <description>1-10 Hertz rTMS will be administered</description>
    <arm_group_label>Active rTMS</arm_group_label>
    <arm_group_label>Sham rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18-30.&#xD;
&#xD;
          2. Use of effective method of birth control for women of childbearing capacity.&#xD;
&#xD;
          3. Willing to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or recent (within the past 6 months) of substance abuse or dependence,&#xD;
             excluding nicotine and caffeine (urine test).&#xD;
&#xD;
          2. Current serious medical illness (self report).&#xD;
&#xD;
          3. History of seizure except those therapeutically induced by ECT (childhood febrile&#xD;
             seizures are acceptable and these subjects may be included in the study), history of&#xD;
             epilepsy in self or first degree relatives, stroke, brain surgery, head injury,&#xD;
             cranial metal implants, known structural brain lesion, devices that may be affected by&#xD;
             rTMS or MRI (pacemaker, medication pump, cochlear implant, implanted brain&#xD;
             stimulator); [TMS Adult Safety Screening (TASS) form].&#xD;
&#xD;
          4. Subjects are unable or unwilling to give informed consent.&#xD;
&#xD;
          5. Diagnosed any Axis I DSM-IV disorder (MINI, DSM-IV)&#xD;
&#xD;
          6. Subjects with a clinically defined neurological disorder including, but not limited&#xD;
             to:&#xD;
&#xD;
               1. Any condition likely to be associated with increased intracranial pressure&#xD;
&#xD;
               2. Space occupying brain lesion.&#xD;
&#xD;
               3. History of stroke.&#xD;
&#xD;
               4. Transient ischemic attack within two years.&#xD;
&#xD;
               5. Cerebral aneurysm.&#xD;
&#xD;
               6. Dementia.&#xD;
&#xD;
               7. Mini Mental Status Exam (MMSE) score of &lt;24.&#xD;
&#xD;
               8. Parkinson's disease.&#xD;
&#xD;
               9. Huntington's disease.&#xD;
&#xD;
             i. Multiple sclerosis.&#xD;
&#xD;
          7. Increased risk of seizure for any reason, including prior diagnosis of increased&#xD;
             intracranial pressure (such as after large infarctions or trauma), or currently taking&#xD;
             medication that lowers the seizure threshold.&#xD;
&#xD;
          8. Subjects with cochlear implants&#xD;
&#xD;
          9. Subjects not willing to tolerate the confinement associated with being in the MRI&#xD;
             scanner.&#xD;
&#xD;
         10. Women who are pregnant or breast-feeding (urine test).&#xD;
&#xD;
         11. Blindness.&#xD;
&#xD;
         12. Inability to read or understand English.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 15, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2017</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TMS</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

